Arcellx Stock Today
| ACLX Stock | USD 88.07 1.00 1.12% |
Performance12 of 100
| Odds Of DistressLess than 17
|
Arcellx is trading at 88.07 as of the 1st of December 2024; that is 1.12 percent decrease since the beginning of the trading day. The stock's open price was 89.07. Arcellx has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Arcellx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of February 2022 | Category Healthcare | Classification Health Care |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 54.07 M outstanding shares of which 4.45 M shares are presently shorted by private and institutional investors with about 6.67 trading days to cover. More on Arcellx
Moving together with Arcellx Stock
| 0.61 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.85 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.81 | BHC | Bausch Health Companies | PairCorr |
| 0.68 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Arcellx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Arcellx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsArcellx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcellx's financial leverage. It provides some insight into what part of Arcellx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arcellx (ACLX) is traded on NASDAQ Exchange in USA. It is located in 800 Bridge Parkway, Redwood City, CA, United States, 94065 and employs 130 people. Arcellx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.82 B. Arcellx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.07 M outstanding shares of which 4.45 M shares are presently shorted by private and institutional investors with about 6.67 trading days to cover.
Arcellx currently holds about 306.99 M in cash with 207.57 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.01.
Check Arcellx Probability Of Bankruptcy
Ownership AllocationArcellx holds a total of 54.07 Million outstanding shares. The majority of Arcellx outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcellx to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcellx. Please pay attention to any change in the institutional holdings of Arcellx as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million seventy-seven thousand two hundred thirty-two invesors are currently shorting Arcellx expressing very little confidence in its future performance.
Check Arcellx Ownership Details
Arcellx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Suvretta Capital Management, Llc | 2024-06-30 | 1.5 M | |
| Cormorant Asset Management, Llc | 2024-09-30 | 1.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 975 K | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 944.6 K | |
| Lord, Abbett & Co Llc | 2024-09-30 | 891.8 K | |
| Vestal Point Capital Lp | 2024-06-30 | 675 K | |
| Great Point Partners Llc | 2024-06-30 | 492 K | |
| Deutsche Bank Ag | 2024-06-30 | 446.5 K | |
| Fmr Inc | 2024-09-30 | 6.5 M | |
| Paradigm Biocapital Advisors Lp | 2024-09-30 | 4 M |
Arcellx Historical Income Statement
Arcellx Stock Against Markets
Arcellx Corporate Management
| Michael MBA | Chief Officer | Profile | |
| Aileen Fernandes | Chief Officer | Profile | |
| Kate Aiken | Chief Officer | Profile | |
| Michelle Gilson | Chief Officer | Profile | |
| Myesha Lacy | Chief Officer | Profile | |
| Christopher MD | Chief Officer | Profile | |
| MS JD | General Counsel | Profile |
Already Invested in Arcellx?
The danger of trading Arcellx is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcellx is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcellx. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcellx is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.